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Introduction: The comparative value and suitability of outcome measures are uncertain in 
chronic inflammatory demyelinating polyneuropathy (CIDP).  
Methods: We studied 35 patients with CIDP using the Overall Neuropathy Limitation Scale 
(ONLS), the inflammatory Rasch-built Overall Disability Scale (I-RODS) and the Medical 
Research Council Sum Score (MRCSS). 
Results: Significant associations were determined between initial deficit and ONLS (p=0.002) 
and MRCSS improvement (p=0.001), but not I-RODS. A strong inverse correlation was 
observed between disease duration and I-RODS (p=0.002), but not ONLS/MRCSS 
improvement. A strong association was observed between age ≤40 years and I-RODS 
(p=0.001), but not ONLS/MRCSS improvement. Using minimum important differences, 
ONLS and I-RODS sensitivities were comparable (p=0.19).  
Discussion: ONLS and I-RODS are equally sensitive in identifying change. Ease of 
administration, better ability to detect improvement in severe disease, greater amplitude 
responses throughout the disease and in older subjects, favor the ONLS. The I-RODS appears 
more useful in early disease/younger patients.  








The use of disability scales has gained importance in the literature in chronic inflammatory 
demyelinating polyneuropathy (CIDP) in recent years. Their use in research settings has 
become widespread. Although the more recently developed inflammatory Rasch-built Overall 
Disability Scale (I-RODS) (1) has been described as testing a wider range of activities and 
having greater responsiveness, it has not, to date, been used in clinical trials as a primary 
outcome measure. On the other hand, the similar Overall Neuropathy Limitation Scale 
(ONLS) (2) and Inflammatory Neuropathy Cause and Treatment (INCAT) (3) scales have 
remained the preferred primary outcome in research studies (4-8). The INCAT or ONLS have 
the advantage over the I-RODS of being easier and quicker to administer.  
Disability scales are not consistently used in most non-academic institutions (9). Their 
comparative value remains uncertain in clinical practice. The value of score changes, and 
interpretation that may result from them, poses difficulty. The clinical application of the 
concept of minimum important difference (MID) is complex (10). The literature on the 
subject has been focused on methods allowing calculation in a research setting, although, to 
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our knowledge, neither has been directly applied in research trials as a primary outcome 
measure, nor in clinical practice in CIDP (10). Establishing what represents meaningful 
change remains challenging in the absence of an evidence-base regarding the MID. This is 
however highly desirable for clinical management (11). 
The main aims of this analysis were to explore the determinants of change on these existing 
scales in clinical practice, establish MID-defined clinically-applicable cut-offs for use in 
therapeutic management and monitoring, and to compare scale sensitivities with these cut-
offs in evaluating treatment response. 
Methods. 
We retrospectively reviewed electronic hospital records of all patients meeting clinical and 
electrophysiological criteria for “definite” or “probable” CIDP as per European Federation of 
Neurological Societies/Peripheral Nerve Society (EFNS/PNS) Guidelines (12), attending the 
Inflammatory Neuropathy Clinic at Queen Elizabeth Hospital, University Hospitals of 
Birmingham, U.K., between June 2014 and December 2018. Scales required for inclusion in 
this study were the Overall Neuropathy Limitation Scale (ONLS), inflammatory Rasch-built 
Overall Disability Scale (I-RODS) and the Medical Research Council (MRC) sum score 
(MRCSS). Patients who had been assessed by these 3 scales and who had displayed any 
degree of improvement on any of the 3 with therapeutic intervention, were considered as 
“responders” for the purposes of this study and were selected for further analysis. We decided 
on this definition despite the limitations in view of the uncertainties of MIDs in our cohort 
prior to our study and as improvement is defined variably in clinical practice.  
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For each patient, we identified demographics, diagnostic criteria category fulfilment, CIDP 
subtype and treatment given. All scales had been administered pre- and post-therapeutic 
intervention. In the case of de-novo patients, assessments took place between 2 and 4 weeks 
before and after first treatment. Similarly, in all other cases, patients were assessed (i) 2 to 4 
weeks preceding and following re-initiation of treatment after prior withdrawal resulting in 
deterioration, or (ii) 2 to 4 weeks preceding and following re-increase of treatment dose after 
a prior dose reduction which had been followed by deterioration. The MRCSS (out of 80) 
was determined by adding individual scores (0 to 5 for each muscle group) from 8 muscle 
groups bilaterally, including shoulder abductors, elbow flexors, wrist extensors, finger 
abductors, hip flexors, knee flexors, ankle dorsiflexors and extensor hallucis. The ONLS 
score ranging from 0 (best) to 12 (worst) was ascertained by physician-administered 
interview, combining upper limb (out of 5) and lower limb (out of 7) scores. Upper limb 
ONLS grades range from 0 (no symptoms or disability), to 5 (inability to perform purposeful 
arm movements) and lower limb ONLS grades range from 0 (ability to run or climb stairs 
without difficulty), to 7 (inability to perform purposeful leg movements) (2).  The I-RODS 
raw score ranging from 0 (worst) to 48 (best) was determined by physician-administered 
interview of the 24 items on that scale, rating inability (0/2), difficulty with (1/2), or 
normality (2/2) for each task (1).  
Mean improvements on each scale and standard deviations (S.D.) were determined. 
Intercorrelation studies of the MRCSS with ONLS and I-RODS were performed, for initial 
and final measures as well as improvement levels. We attempted to ascertain eventual 
determinants of the amplitude of response for each scale, amongst several co-variates 
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including disability at onset as measured on the studied scale, disease duration, age at onset, 
age at time of analysis and gender. In addition, we calculated, for our cohort, the MID, using 
a validated distribution-based statistical method with ½ S.D., which has been described as 
showing equivalence to anchor-based methods (13, 14). Furthermore, as a distribution-based 
method, ½ S.D. has been found to be a widely valid estimate of the MID across multiple 
studies (15). Responder rates achieved in relation to the closest measurable scores above the 
calculated MID for each scale, were established. We subsequently attempted to determine the 
most sensitive disability scale for use in the clinical setting, with the established MID. This 
was performed by re-defining responder status for each scale using the MID as cut-off and 
calculating the sensitivity in each case (number reaching responder status as per new 
definition/35 x 100). 
Comparison of proportions were performed with Fisher Exact tests and comparisons of 
means by independent t-tests. Correlations were performed using Pearson’s correlation. 
Bonferroni correction was applied for multiple comparisons. Correlations levels were defined 
as “perfect”, “very strong”, “moderate”, “fair”, “poor”, or “none”, as previously suggested for 
medical research (16). Multiple regression was used to ascertain eventual independent 
associations. Statistical analyses were performed using SPSS 25.0 software.  
This analysis was performed as part of a retrospective Clinical Audit approved and registered 
at University Hospitals of Birmingham, U.K. on evaluation of the use of outcome measures 
for inflammatory neuropathy in our Inflammatory Clinic (CARMS 14615, September 2018).  
 















We recruited 35 patients in the current study. The main characteristics of the studied cohort 
are summarised in Table 1.  
The mean initial MRCSS was 62.29 (S.D.: 8.32), mean initial ONLS was 4.54 (S.D.: 1.42) 
and mean initial I-RODS was 26.26 (S.D.: 8.47). Mean final MRCSS was 73.57 (S.D.: 7.27), 
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mean final ONLS was 2.51 (S.D.: 1.48) and mean final I-RODS was 34.94 (S.D.: 8.92). 
Mean MRCSS improvement was 11.20 (S.D.: 6.35; range: 2-29), mean ONLS improvement 
was 2.03 (S.D.: 1.54; range: 0-7) and mean I-RODS improvement was 8.66 (S.D.: 6.87; 
range: 0-29).  
Initial MRCSS correlated fairly with initial ONLS scores (r=-0.526; p=0.001) and with initial 
I-RODS scores (r=0.553; p=0.001). Initial ONLS and I-RODS scores were also fairly inter-
correlated (r=-0.484; p=0.003). Final MRCSS correlated moderately with final ONLS scores 
(r=-0.662; p<0.001) and I-RODS (r=0.678; p<0.001). Final ONLS and I-RODS scores were 
very strongly correlated (r=-0.822; p<0.001).  
The improvement in MRCSS and ONLS scores were moderately correlated (r= 0.633; 
p<0.001), as were the improvements in ONLS and I-RODS scores (r=0.664; p<0.001). A fair 
correlation was ascertained between the MRCSS improvement and the I-RODS improvement 
(r=0.412; p=0.014).  
Table 2. summarises results of correlation studies with the 5 studied potential determinants of 
responses for each of the 3 scales (Bonferroni-corrected; significance p<0.01). Fair 
correlations were ascertained between pre-treatment deficit and the improvement achieved 
for the MRCSS and the ONLS, but none was found for the I-RODS. A fair inverse 
correlation was ascertained between disease duration and I-RODS improvement but none was 
found for the other 2 scales. Age of onset did not correlate with improvement on any of the 3 
scales. A fair correlation was found between age ≤40 years and I-RODS improvement but 
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none observed for the other 2 scales. Gender did not correlate with improvement on any 
scale.  
Multiple linear regression demonstrated that I-RODS improvement was independently 
inversely associated with disease duration (p=0.005) and age <40 years at time of analysis 
(p=0.002).  
The MID determined with the distribution method using the ½ S.D., was 3.18 for MRCSS, 
0.77 for ONLS and 3.44 for I-RODS. Using corresponding minimal clinically-applicable cut-
offs, i.e. 4 points for the MRCSS, 1 point for the ONLS and 4 points for the I-RODS, the 
sensitivity of the MRCSS was 94.3% (33/35), that of the ONLS was of 91.4% (32/35), and 
that of the I-RODS, of 77.1% (27/35), in establishing treatment response. The differences 













We studied 3 currently commonly used clinical scales in CIDP management. The MRCSS is 
exclusively muscle strength-related and has been used in clinical trials and practice for 
several decades. Recent studies have challenged its validity and questioned its reliability (17). 
It remains however in its current form of six-point testing, as utilised in our unit, still 
commonly used in practice. The ONLS was derived from the Guy’s disability scale which 
also in the interim led to use of the INCAT (Inflammatory Neuropathy Cause and Treatment) 
scale (2). Despite poor content and structural validity, the INCAT/ONLS are considered 
reliable and responsive (18). The minimum detectable change with the INCAT was however 
found greater than the derived MID from patients participating in a research study (19), 
suggesting suboptimal sensitivity to detect improvement in some subjects, compounded by 
inadequately low weight attributed to proximal arm function and stamina-related activities 
(18). In more recent years, the inflammatory Rasch-built Overall Disability Scale (I-RODS) 
has been developed (1). Compared to the ONLS, the I-RODS offers assessment of a wider 
range of item difficulties, and therefore evaluation of patients of different ability. It has, as a 
result, been adopted in daily practice in many centres. 
We found high levels of correlation between MRCSS and ONLS improvement levels and 
between ONLS and I-RODS changes. Only moderate correlation was found between MRCSS 
and I-RODS and this is consistent with the latter scale exploring non-strength-related 
disabilities particularly stamina-related tasks and sensory dysfunction.  
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We ascertained that greater impairment at baseline was more likely to be followed by larger 
score improvements for the MRCSS and the ONLS but not I-RODS. This represents a benefit 
of the former 2 scales, as allows easier recognition of amelioration. We found a significant 
inverse association of disease duration with I-RODS improvement level. No association was 
ascertained with ONLS or MRCSS improvement. The I-RODS therefore appeared to 
demonstrate greater score changes and be of greater value, in early disease. These findings 
suggest the greater usefulness of the I-RODS in early CIDP with shorter disease duration but 
also conversely, that the ONLS and MRCSS are equally useful in all disease stages, including 
later in its course. It is possible that the I-RODS shows more change in early disease as larger 
differences may be observed on treatment initiation, rather than later when treatment changes 
are done, when careful attention is paid to change for decisions to re-introduce treatment or 
increase doses. 
In relation to age, we found a strong association between age ≤40 years at time of evaluation 
and I-RODS improvement.  There was however no correlation with the degree of ONLS or 
MRCSS improvement. This suggests limited practical clinical value of the I-RODS in older 
patients with CIDP, the mean age of our cohort of 58.74 years being similar to those of 
previously described populations, and in keeping with CIDP being a disease more common in 
older subjects (20-22). Intuitively, the use of the I-RODS, in view of the range of disability 
items considered, would be likely more helpful in younger and therefore often more active 
subjects, and our results support this impression. The independent associations we found 
between disease duration and age <40 years at time of study and the I-RODS score 
improvement, highlight the impact of both of these factors individually on the value of this 
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scale. Variability over time has been described with Patient Reported Outcome Measures 
(PROM) in other disorders such as ankylosing spondylitis (23). In addition, trends for greater 
improvement in younger subjects has been reported with other PROMs, such as the Oxford 
Knee Score, after total knee replacements (24). It is likely that age and the timing of 
assessment are of similar importance in CIDP, and that the current “one scale for all and at all 
times” approach to CIDP clinical monitoring and management, may be unsuitable. 
The MIDs determined from our cohort were comparable to those previously published from 
research studies for both the ONLS (comparing to published INCAT score MID) (19) and I-
RODS (10). We found that using these MIDs, the ONLS had comparable sensitivity to the I-
RODS in identifying clinically-meaningful improvement. The MID for MRCSS found in our 
subjects (3.18) was otherwise comparable to that found both with the distribution method 
using ½ S.D. (3.53) and with the anchor-based approach, in a research setting (3.07) (10).   
Our study has several limitations. The number of patients studied was relatively small and 
from a single centre. The population studied comprised patients of different CIDP subtypes 
including LSS and newly described variants with anti-paranodal antibodies (25) and was 
therefore not homogeneous. This methodology is however consistent with that of previous 
studies (10) and is consistent with CIDP cohort distribution as encountered in clinical 
practice. We opted to include the different CIDP subtypes as atypical forms may evolve 
progressively with time into the typical phenotype as recently demonstrated (26), which may 
make rigorous separation of the subtypes illusory. Also, the administration of scales was 
performed by a clinician/interviewer familiar with the scales, which may not be the routine 
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practice of many units, where the I-RODS is often completed by patients themselves. Finally, 
the use of distribution methods with ½ S.D. for ascertainment of MID, although previously 
found equivalent to the anchor-based technique, was not validated by the latter in our study. 
In conclusion, the ONLS and the I-RODS, using clinical practice-derived MIDs, appear of 
comparable sensitivity in identifying change in treated CIDP in clinical practice. This 
challenges the impression of greater adequacy of more detailed evaluations in all subjects and 
at all times. It is noteworthy that our findings appear consistent with the detailed results of a 
recent phase 3 trial of subcutaneous immunoglobulin for CIDP (8). In this trial, although 
58.8% of the placebo group relapsed as defined by a modified-INCAT score deterioration of 
1 point, with a median change from baseline of 1.0 point, the median change of the percentile 
I-RODS score was only of -3.0 (1), and therefore smaller than a MID of 4 raw points, as 
found previously (10), and confirmed by our current study. Ease of administration with, an 
albeit non-significant, better relative sensitivity, better ability to detect improvement in more 
severely affected subjects, greater value throughout the disease and older subjects, appear 
favour the ONLS in CIDP, which is a long-term chronic illness, more prevalent with age. The 
I-RODS appears more helpful early in the disease and in younger patients. The MRCSS, 
despite its described and recognised limitations, may in view of its benefits in late disease 
stages and older patients, remain of potential benefit in the global evaluation, although it 
cannot clearly, in isolation, be the sole driver of therapeutic decisions. We believe the 
MRCSS may also help to differentiate CIDP-related deficits to those resulting from other 
non-neurological causes producing restrictions of mobility and function, although this 
requires further study, as conversely, pain from any cause may alter MRC ratings. This is, 
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again, especially relevant in a disease more frequent with age, and therefore, often associated 
with co-morbidities.  
Further larger multicentre prospective studies of clinical practice are needed to determine the 
precise place of scale choice in the assessment of different patients, with different types of 






Table 1.: Demographic Characteristics of 35 patients with treated CIDP  
 
Characteristic Mean ± SD or Number 
(%) 
Mean age 58.74 (±13.74) years 
Mean age at onset 52.63 (±14.10) years 
Mean disease duration 71.94 (±72.35) months 
Gender  
     Male 24 (68.5%) 
     Female 11 (31.5%) 
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EFNS/PNS Guidelines Diagnostic category  
     Definite 31 (88.6%) 
     Probable 4 (11.4%) 
CIDP Subtype  
    Typical 30 (85.7%) 
    Lewis-Sumner Syndrome 4 (11.4%) 
    Pure motor 1 (2.9%) 
Treatment  
    IVIg 28 (80%) 
    IV Methylprednisolone 5 (14.3%) 
    Rituximab 2 (5.7%) 
 
Abbreviations: 
CIDP: chronic inflammatory demyelinating polyneuropathy 






Table 2. Correlations between improvements in MRCSS, ONLS and I-RODS and pre-treatment 





















NS NS NS NS 




NS NS NS NS 
I-RODS 
improvement 





r = Pearson’s correlation; NS: non-significant- Bonferroni correction applied- significance: p<0.01 
 
Abbreviations: 
MRCSS: Medical Research Council Sum Score 
ONLS: Overall Neuropathy Limitation Scale 
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